Literature DB >> 30368569

Is adjuvant chemotherapy necessary for locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery? A systematic review and meta-analysis.

Bin Ma1, Yupeng Ren1, Yue Chen1, Bo Lian1, Peng Jiang1, Yongmin Li1, Yan Shang1, Qingkai Meng2.   

Abstract

PURPOSE: Current clinical guidelines recommended the routine use of adjuvant chemotherapy for locally advanced rectal cancer (LARC) patients. However, the effects of adjuvant chemotherapy in patients with pathological complete response (pCR) after neoadjuvant chemoradiotherapy and radical surgery showed discrepancies in different investigations.
METHODS: A systematic review and meta-analysis were conducted using PubMed, Embase and Web of Science databases. All original comparative studies published in English that were related to adjuvant versus non-adjuvant chemotherapy for LARC patients with pCR were included.
RESULTS: A total of 6 studies based on 18 centres or databases involving 2948 rectal cancer patients with pCR (adjuvant group = 1324, non-adjuvant group = 1624) were included in our overall analysis. Based on our meta-analysis, LARC patients with pCR who received adjuvant chemotherapy showed a significantly improved overall survival (OS) when compared to patients with observation (HR = 0.65, 95% CI = 0.46-0.90, P = 0.01). In addition, investigations focused on this issue based on the National Cancer Database (NCDB) were systematically reviewed in our current study. Evidence from all three analyses demonstrated that LARC patients with clinical nodal positive disease that achieved pCR might benefit the most from additional adjuvant chemotherapy.
CONCLUSION: Our meta-analysis indicated that adjuvant chemotherapy is associated with improved OS in LARC patients with pCR after neoadjuvant chemoradiotherapy and radical surgery.

Entities:  

Keywords:  Adjuvant chemotherapy; Locally advanced rectal cancer; Meta-analysis; Pathological complete response

Mesh:

Year:  2018        PMID: 30368569     DOI: 10.1007/s00384-018-3181-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  36 in total

1.  Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy?

Authors:  Ravi P Kiran; Hasan T Kirat; Adele N Burgess; Pasha J Nisar; Matthew F Kalady; Ian C Lavery
Journal:  Ann Surg Oncol       Date:  2011-09-21       Impact factor: 5.344

2.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

3.  Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results.

Authors:  Frank L Schmidt; In-Sue Oh; Theodore L Hayes
Journal:  Br J Math Stat Psychol       Date:  2007-11-13       Impact factor: 3.380

4.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Authors:  Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

Review 5.  Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  S T Martin; H M Heneghan; D C Winter
Journal:  Br J Surg       Date:  2012-02-23       Impact factor: 6.939

Review 6.  Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials.

Authors:  K Bujko; R Glynne-Jones; M Bujko
Journal:  Ann Oncol       Date:  2010-03-15       Impact factor: 32.976

7.  Capecitabine as adjuvant treatment for stage III colon cancer.

Authors:  Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

8.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.

Authors:  Laurence Collette; Jean-Francois Bosset; Marcel den Dulk; France Nguyen; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Marianne Piérart; Gilles Calais
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  6 in total

1.  Compliance to Adjuvant Chemotherapy of Patients Who Underwent Surgery for Rectal Cancer: Report from a Multi-institutional Research Network.

Authors:  Giulio M Mari; Dario Maggioni; Jacopo Crippa; Andrea T M Costanzi; Mauro A Scotti; Vittorio Giardini; Mattia Garancini; Eugenio Cocozza; Giacomo Borroni; Ilaria Benzoni; Mario Martinotti; Luigi Totaro; Matteo Origi; Michele Mazzola; Giovanni Ferrari; Pietro Achilli; Antonio Ziccarelli; Antonio Martino; Roberto Petri; Francesca Botta; Vincenzo Bagnardi; Giacomo Pugliese; Antonello Forgione; Raffaele Pugliese
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

2.  Adjuvant chemotherapy in rectal cancer patients who achieved a pathological complete response after preoperative chemoradiotherapy: a systematic review and meta-analysis.

Authors:  Yu Jin Lim; Youngkyong Kim; Moonkyoo Kong
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

3.  ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.

Authors:  Qingguo Li; Dakui Luo; Ji Zhu; Lifeng Yang; Qi Liu; Yanlei Ma; Lei Liang; Sanjun Cai; Zhen Zhang; Xinxiang Li
Journal:  BMC Cancer       Date:  2019-11-15       Impact factor: 4.430

4.  Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.

Authors:  Yizi Wang; Bin Ma; Shize Yang; Wenya Li; Peiwen Li
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

5.  T-stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics.

Authors:  Ian P Hayes; Elasma Milanzi; Rachel M Pelly; Peter Gibbs; Jeanette C Reece
Journal:  J Surg Oncol       Date:  2022-05-30       Impact factor: 2.885

6.  Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.

Authors:  Ting Jiang; Shuang Liu; Xiaojun Wu; Xiaoqing Liu; Weizhan Li; Shanfei Yang; Peiqiang Cai; Shaoyan Xi; Zhifan Zeng; Yuanhong Gao; Gong Chen; Weiwei Xiao
Journal:  Cancer Manag Res       Date:  2021-06-15       Impact factor: 3.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.